BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liguori C, Placidi F, Albanese M, Nuccetelli M, Izzi F, Marciani MG, Mercuri NB, Bernardini S, Romigi A. CSF beta-amyloid levels are altered in narcolepsy: a link with the inflammatory hypothesis? J Sleep Res 2014;23:420-4. [DOI: 10.1111/jsr.12130] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Takenoshita S, Sakai N, Chiba Y, Matsumura M, Yamaguchi M, Nishino S. An overview of hypocretin based therapy in narcolepsy. Expert Opinion on Investigational Drugs 2018;27:389-406. [DOI: 10.1080/13543784.2018.1459561] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
2 Romigi A, Bari M, Liguori C, Izzi F, Rapino C, Nuccetelli M, Battista N, Bernardini S, Centonze D, Mercuri NB, Placidi F, Maccarrone M. CSF Levels of the Endocannabinoid Anandamide are Reduced in Patients with Untreated Narcolepsy Type 1: A Pilot Study. CNS Neurol Disord Drug Targets 2020;19:142-7. [PMID: 32148204 DOI: 10.2174/1871527319666200309115602] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Heier M, Gautvik K. What happens in the brain in narcolepsy over time? Sleep Medicine 2014;15:1427. [DOI: 10.1016/j.sleep.2014.07.003] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Lecendreux M, Churlaud G, Pitoiset F, Regnault A, Tran TA, Liblau R, Klatzmann D, Rosenzwajg M. Narcolepsy Type 1 Is Associated with a Systemic Increase and Activation of Regulatory T Cells and with a Systemic Activation of Global T Cells. PLoS One 2017;12:e0169836. [PMID: 28107375 DOI: 10.1371/journal.pone.0169836] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
5 Liguori C, Romigi A, Mercuri NB, Nuccetelli M, Izzi F, Albanese M, Sancesario G, Martorana A, Sancesario GM, Bernardini S, Marciani MG, Placidi F. Cerebrospinal-fluid orexin levels and daytime somnolence in frontotemporal dementia. J Neurol 2014;261:1832-6. [DOI: 10.1007/s00415-014-7455-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
6 Romigi A, Vitrani G, Lo Giudice T, Centonze D, Franco V. Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy. Drug Des Devel Ther 2018;12:2665-75. [PMID: 30214155 DOI: 10.2147/DDDT.S101145] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 5.3] [Reference Citation Analysis]
7 Takahashi T, Noriaki S, Matsumura M, Li C, Takahashi K, Nishino S. Advances in pharmaceutical treatment options for narcolepsy. Expert Opinion on Orphan Drugs 2018;6:597-610. [DOI: 10.1080/21678707.2018.1521267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Lindström M, Schinkelshoek M, Tienari PJ, Kukkonen JP, Renkonen R, Fronczek R, Lammers GJ, Itkonen O. Orexin-A measurement in narcolepsy: A stability study and a comparison of LC-MS/MS and immunoassays. Clin Biochem 2021;90:34-9. [PMID: 33539807 DOI: 10.1016/j.clinbiochem.2021.01.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Baiardi S, Pizza F, Polischi B, Moresco M, Abu-Rumeileh S, Plazzi G, Parchi P. Cerebrospinal fluid biomarkers of neurodegeneration in narcolepsy type 1. Sleep 2020;43:zsz215. [PMID: 31552425 DOI: 10.1093/sleep/zsz215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ettore E, Bakardjian H, Solé M, Levy Nogueira M, Habert M, Gabelle A, Dubois B, Robert P, David R. Relationships between objectives sleep parameters and brain amyloid load in subjects at risk for Alzheimer’s disease: the INSIGHT-preAD Study. Sleep 2019;42:zsz137. [DOI: 10.1093/sleep/zsz137] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
11 Cedernaes J, Osorio RS, Varga AW, Kam K, Schiöth HB, Benedict C. Candidate mechanisms underlying the association between sleep-wake disruptions and Alzheimer's disease. Sleep Med Rev 2017;31:102-11. [PMID: 26996255 DOI: 10.1016/j.smrv.2016.02.002] [Cited by in Crossref: 95] [Cited by in F6Publishing: 90] [Article Influence: 15.8] [Reference Citation Analysis]
12 Schirinzi T, Landi D, Liguori C. COVID-19: dealing with a potential risk factor for chronic neurological disorders. J Neurol 2021;268:1171-8. [PMID: 32852580 DOI: 10.1007/s00415-020-10131-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
13 Marques TM, Van Rumund A, Kuiperij HB, Verbeek MM. Biomarkers in cerebrospinal fluid for synucleinopathies, tauopathies, and other neurodegenerative disorders. Cerebrospinal Fluid in Neurologic Disorders. Elsevier; 2018. pp. 99-113. [DOI: 10.1016/b978-0-12-804279-3.00007-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Gabelle A, Jaussent I, Bouallègue FB, Lehmann S, Lopez R, Barateau L, Grasselli C, Pesenti C, de Verbizier D, Béziat S, Mariano-Goulart D, Carlander B, Dauvilliers Y; Alzheimer's Disease Neuroimaging Initiative., Multi-Domain Intervention Alzheimer's Prevention Trial study groups. Reduced brain amyloid burden in elderly patients with narcolepsy type 1. Ann Neurol 2019;85:74-83. [PMID: 30387527 DOI: 10.1002/ana.25373] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
15 Liguori C, Dinallo V, Pieri M, Izzi F, Romigi A, Ialongo C, Marciani MG, Bernardini S, Mercuri NB, Placidi F. MicroRNA expression is dysregulated in narcolepsy: a new evidence? Sleep Medicine 2015;16:1027-8. [DOI: 10.1016/j.sleep.2015.03.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
16 Dijk DJ. Not so fast: sleep and media use. J Sleep Res 2014;23:363. [PMID: 25073803 DOI: 10.1111/jsr.12212] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Liguori C, Spanetta M, Romoli M, Placidi F, Nardi Cesarini E, Mercuri NB, Costa C. Sleep disorders and late-onset epilepsy of unknown origin: Understanding new trajectories to brain amyloidopathy. Mech Ageing Dev 2021;194:111434. [PMID: 33444630 DOI: 10.1016/j.mad.2021.111434] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Liguori C, Nuccetelli M, Izzi F, Sancesario G, Romigi A, Martorana A, Amoroso C, Bernardini S, Marciani MG, Mercuri NB, Placidi F. Rapid eye movement sleep disruption and sleep fragmentation are associated with increased orexin-A cerebrospinal-fluid levels in mild cognitive impairment due to Alzheimer's disease. Neurobiology of Aging 2016;40:120-6. [DOI: 10.1016/j.neurobiolaging.2016.01.007] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 9.3] [Reference Citation Analysis]
19 Liguori C, Chiaravalloti A, Nuccetelli M, Izzi F, Sancesario G, Cimini A, Bernardini S, Schillaci O, Mercuri NB, Fabio P. Hypothalamic dysfunction is related to sleep impairment and CSF biomarkers in Alzheimer's disease. J Neurol 2017;264:2215-23. [PMID: 28900724 DOI: 10.1007/s00415-017-8613-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
20 Hirtz C, Vialaret J, Gabelle A, Nowak N, Dauvilliers Y, Lehmann S. From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid. Sci Rep 2016;6:25162. [PMID: 27165941 DOI: 10.1038/srep25162] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
21 Engström M, Hallböök T, Szakacs A, Karlsson T, Landtblom AM. Functional magnetic resonance imaging in narcolepsy and the kleine-levin syndrome. Front Neurol 2014;5:105. [PMID: 25009530 DOI: 10.3389/fneur.2014.00105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
22 Mogavero MP, Silvani A, DelRosso LM, Salemi M, Ferri R. Focus on the Complex Interconnection between Cancer, Narcolepsy and Other Neurodegenerative Diseases: A Possible Case of Orexin-Dependent Inverse Comorbidity. Cancers (Basel) 2021;13:2612. [PMID: 34073579 DOI: 10.3390/cancers13112612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Jiang X, Zhang T, Wang H, Wang T, Qin M, Bao P, Wang R, Liu Y, Chang HC, Yan J, Xu J. Neurodegeneration-associated FUS is a novel regulator of circadian gene expression. Transl Neurodegener 2018;7:24. [PMID: 30338063 DOI: 10.1186/s40035-018-0131-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
24 Liguori C, Moresco M, Izzi F, Mercuri NB, Plazzi G, Placidi F. New revolution in the assessment of cerebrospinal fluid orexin‐A: Enzyme‐linked immunosorbent assay! Psychiatry Clin Neurosci 2019;73:194-5. [DOI: 10.1111/pcn.12816] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
25 Wang C, Holtzman DM. Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors. Neuropsychopharmacology 2020;45:104-20. [PMID: 31408876 DOI: 10.1038/s41386-019-0478-5] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 15.7] [Reference Citation Analysis]
26 Liguori C, Placidi F, Izzi F, Albanese M, Nuccetelli M, Bernardini S, Marciani MG, Mercuri NB, Romigi A. May CSF beta-amyloid and tau proteins levels be influenced by long treatment duration and stable medication in narcolepsy? Sleep Medicine 2014;15:1424. [DOI: 10.1016/j.sleep.2014.07.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
27 Romigi A, Liguori C, Izzi F, Albanese M, Marchi A, Mancini C, Tarquini E, Mercuri NB, Placidi F. Oral l-carnitine as treatment for narcolepsy without cataplexy during pregnancy: A case report. Journal of the Neurological Sciences 2015;348:282-3. [DOI: 10.1016/j.jns.2014.11.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
28 Berteotti C, Liguori C, Pace M. Dysregulation of the orexin/hypocretin system is not limited to narcolepsy but has far-reaching implications for neurological disorders. Eur J Neurosci 2021;53:1136-54. [PMID: 33290595 DOI: 10.1111/ejn.15077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Al Suwayri SM, BaHammam AS. The "Known Unknowns" of Kleine-Levin Syndrome: A Review and Future Prospects. Sleep Med Clin 2017;12:345-58. [PMID: 28778233 DOI: 10.1016/j.jsmc.2017.03.012] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
30 Liguori C, Placidi F, Izzi F, Nuccetelli M, Bernardini S, Sarpa MG, Cum F, Marciani MG, Mercuri NB, Romigi A. Beta-amyloid and phosphorylated tau metabolism changes in narcolepsy over time. Sleep Breath 2016;20:277-83. [DOI: 10.1007/s11325-015-1305-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
31 Liguori C. Orexin and Alzheimer’s Disease. In: Lawrence AJ, de Lecea L, editors. Behavioral Neuroscience of Orexin/Hypocretin. Cham: Springer International Publishing; 2017. pp. 305-22. [DOI: 10.1007/7854_2016_50] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
32 Morrone CD, Liu M, Black SE, McLaurin J. Interaction between therapeutic interventions for Alzheimer's disease and physiological Aβ clearance mechanisms. Front Aging Neurosci 2015;7:64. [PMID: 25999850 DOI: 10.3389/fnagi.2015.00064] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]